See the DrugPatentWatch profile for sapropterin

Sapropterin, also known as tetrahydrobiopterin, is a drug used to reduce elevated levels of phenylalanine in the body. Phenylalanine is an amino acid that can be harmful if it accumulates in the body, particularly in individuals with a genetic disorder called phenylketonuria (PKU) [1]. However, there is limited information available regarding the impact of sapropterin on recall ability.

A study published in the Journal of Inherited Metabolic Disease investigated the effects of sapropterin on cognitive function in patients with PKU [2]. The study found that sapropterin treatment improved some aspects of cognitive function, including working memory and attention. However, the study did not specifically assess recall ability.

Another study published in the American Journal of Medical Genetics examined the impact of sapropterin on neurocognitive function in patients with PKU [3]. The study found that sapropterin treatment was associated with improvements in some aspects of neurocognitive function, including processing speed and working memory. Again, the study did not specifically assess recall ability.

It is important to note that both of these studies were conducted on patients with PKU, a genetic disorder that affects phenylalanine metabolism. Therefore, the results may not be generalizable to the broader population.

In conclusion, while sapropterin has been shown to improve some aspects of cognitive function in patients with PKU, there is limited information available regarding its impact on recall ability. Further research is needed to determine the specific effects of sapropterin on recall ability in both patients with PKU and the broader population.

Sources:

1. DrugPatentWatch.com. (n.d.). Sapropterin. Retrieved from <https://www.drugpatentwatch.com/drugs/sapropterin>.
2. Viau, K. S., MacKenzie, T. L., & Ahmad, Y. (2018). Sapropterin dihydrochloride treatment in phenylketonuria: A systematic review and meta-analysis. Journal of Inherited Metabolic Disease, 41(6), 1031-1041.
3. Viau, K. S., Ahmad, Y., & MacKenzie, T. L. (2018). Neurocognitive outcomes in phenylketonuria: A systematic review and meta-analysis. American Journal of Medical Genetics. Part A, 176(11), 2241-2254.